3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
3
Phase 1
3
Phase NA
1
Phase 4
1
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
245
Carcinoma, Non-Small-Cell Lung
226
Prostatic Neoplasms
115
Neoplasms
106
Multiple Myeloma
91
Neoplasm Metastasis
77
Colorectal Neoplasms
73
Parkinson Disease 4, Autosomal Dominant Lewy Body
69
Lung Neoplasms
67
Ovarian Neoplasms
62
Leukemia, Myeloid, Acute
50
Carcinoma, Hepatocellular
48
Melanoma
46
Leukemia, Lymphocytic, Chronic, B-Cell
44
Carcinoma, Renal Cell
43
Stomach Neoplasms
42
Urinary Bladder Neoplasms
41
Squamous Cell Carcinoma of Head and Neck
41
Triple Negative Breast Neoplasms
40
Brain Neoplasms
40
Recurrence
39
Myasthenia Gravis
38
Small Cell Lung Carcinoma
36
Lymphoma, Follicular
35
Nasopharyngeal Carcinoma
34
Head and Neck Neoplasms
34
Pancreatic Neoplasms
32
Rectal Neoplasms
30
Lymphoma, Large B-Cell, Diffuse
30
Colonic Neoplasms
29
Interventions
acalabrutinib
1
Vincristine
1
Rituximab
1
Prednisone
1
Doxorubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphatic Diseases
×
1 year
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled